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Background: The purpose of this research was to evaluate the therapeutic effects and prognostic factors of
transanal local excision (TAE) for rectal cancer.
Methods: We retrospectively analyzed 116 cases that underwent TAE for rectal cancer from 1995 to 2008. A Cox
regression analysis was used to analyze prognostic factors.
Results: The survival times for the patients were from 14 to 160.5 months (median time, 58.5 months). The 5-year
and 10-year overall survival rates were 72% and 53%, respectively. In all 16 cases experienced local recurrence
(13.8%). Pathological type, recurrence or metastasis, and depth of infiltration (T stage) were the prognostic factors
according to the univariate analysis, and the latter two were independent factors affecting patient prognosis. For
patients with T1 stage who underwent adjuvant radiotherapy, there was no local recurrence; for those in T2 stage,
the local recurrence rate was 14.6%. In addition, there was no difference between the patients who received radiotherapy
and those who did not (T1: P = 0.260, T2: P = 0.262 for survival rate and T1: P = 0.480, T2: P = 0.560 for recurrence).
Conclusions: The result of TAE for rectal cancer is satisfactory for T1 stage tumors, but it is not suitable for T2 stage
tumors.
Keywords: rectal cancer, transanal local excision, survival, recurrence, radiotherapyHighlights
 Material for rectal cancer patients who underwent
TAE were retrospectively collected.
 Survival rate and recurrence rate of the patients
were analyzed.
 Recurrence or metastasis and depth of infiltration
were prognostic factors.
 Adjuvant radiotherapy caused no significant clinical
outcomes.
 Patients in T2 stage had a higher local recurrence rate.Background
Rectal cancer is the result of uncontrolled cell growth in
the colon or rectum (parts of the large intestine), or in the
appendix. It is a significant source of morbidity and mortal-
ity. The mortality rate in mainland China began to increase
from 1995, especially in urban areas [1,2]. Low rectal cancer* Correspondence: XiaoxiaLixxl3@163.com
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unless otherwise stated.accounts for approximately 70% of the rectal cancers in
China [3]. Surgical excision of the affected segment of the
bowel is the mainstay treatment for rectal cancer [4].
Transanal local excision (TAE) is an acceptable curative
operation for low rectal cancer [5]. This treatment at an
early stage has multiple advantages, including non-
invasion of the abdominal cavity, minimal trauma and no
disturbance of urinary and sexual functions [6]. Mean-
while, TAE also makes it possible to avoid postoperative
colostomy [7,8]. Currently, there are controversies about
patient selection for TAE treatment. In this retrospective
study, we investigated the efficacy of TAE treatment for
rectal cancer patients at an early stage, as well as the prog-
nostic factors in this treatment.Methods
Patients
Clinical material for patients with rectal cancer treated be-
tween 1995 and 2008 by TAE at Liaoning Cancer Hospital
and the Fourth Affiliated Hospital of the China Medical
University were collected. The patients underwent a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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imaging (MRI) scan and digital rectal examination. Pa-
tients within stage II of rectal cancer according to the Na-
tional Comprehensive Cancer Network (NCCN) guideline
were included, while those at a higher stage or who did
not agree to the TAE regimen were excluded.
Treatments
Surgical treatment
Preoperatively, evaluation of the tumors, including loca-
tion, size, and stage, was performed using an entero-
scope, pelvic CT/MRI and digital rectal examination [9].
Then, all tumors were treated by TAE. Dorsal lithotomy
or the prone jackknife position was used according to
the location of the tumor, that is, the distance from the
anal verge to the distal tumor margin. Firstly, routine
sterilization was conducted, followed by a 4- or 5-finger-
wide expansion of the anus. Secondly, after groovy disin-
fection, the tumors were exposed. Finally, the tumors,
together with the basal part and normal tissues within
1 cm of the lesions, were excised entirely. The excised
specimens, resection margins and the basal parts were
sent for pathological examination.
Adjuvant radiation therapy
After TAE surgery, 52 patients received adjuvant radiation
therapy (RT) with the energy ranging from 6 to 10 MV ac-
cording to their tolerance degree and the dose limitation
for intestinal radiation. The detailed treatments including
the radiation doses are presented in Table 1.
Statistical analysis
Survival analysis was performed with the SPSS 15.0 pack-
age. The Cox proportional hazard model was used to
analyze the prognostic factors. The univariate analysis
used the Kaplan–Meier method, survival rates were
assessed using a life table and comparisons between sur-
vival rates were performed using a log rank test (α = 0.05).
Results
Clinical material
A total of 116 cases (53 male and 63 female; 0.8:1.0) were
included in this retrospective study. Their ages ranged
from 30 to 80 with a median of 61. Preoperatively, 34
cases were diagnosed as T1, 77 cases as T2, and 5 cases asTable 1 Radiotherapy treatment for 52 patients
Radioactive source Doses (Gy) Number of cases
Cs-137 15–50 13
Ir-192 45 2
Cs-137 and Ir-192 15 + 30 2
Co-60 10–60 14
X-ray 21–67 21T3 cancers; and postoperatively, 7 cases were diagnosed as
Tis, 24 cases as T1, 81 cases as T2, and 4 cases as T3. Be-
sides, 52 patients received RT. All patients were treated
with TAE, while one patient undertook a second TAE
treatment. Six patients converted to a Miles operation,
and one patient converted to a low anterior resection.
Complications after the operation occurred in six cases
(5.2%), among which five cases had a hemorrhage of more
than 50 ml during the operation, and the bleeding was
controlled after sufficient hemostatic measures and symp-
tomatic treatment. One case developed a portal vein infec-
tion and septicemia, and the condition improved after
anti-infective treatment.
Follow-up and survival analysis
Two patients were lost to follow-up, while the follow-up
rate was 98.3%. The survival time was 14 to 160.5 months,
of which the median was 58.5 months. The 5-year and 10-
year overall survival rates were 72% and 53%, respectively.
In total, 16 patients developed a local recurrence of the
tumor during the follow-up period (recurrence rate,
13.8%), while distant metastasis occurred in 13 cases
(11.2%), and local recurrence combined with metastasis
occurred in 3 cases (2.6%).
Efficacy of adjuvant radiation therapy
Statistical comparisons of the survival rate and recurrence
rate were performed between patients who received TAE
and those received both TAE and adjuvant RT at the T1
and T2 stages (Table 2). No statistical difference in survival
rate was found between the two groups (T1: P = 0.184
(Figure 1A); T2: P = 0.356 (Figure 1B)). In addition, there
were also no significant differences in local recurrence
rate between the TAE and TAE+RT groups at the T1
(P = 0.480, Figure 1C) and T2 stages (P = 0.560, Figure 1D).
Analysis of prognostic factors
We investigated the prognostic factors for TAE treat-
ment using univariate analysis (Table 3). We found that
pathological type, recurrence or metastasis, and depth of
infiltration (T stage) were the prognostic factors. In the
further Cox regression analysis, we detected that among
the prognostic factors, recurrence or metastasis, and
depth of infiltration were independent factors (Table 4)
affecting patients’ prognosis. Patients with a higher T
stage or with recurrence or metastasis have a higher risk
of death.
Discussion
Reducing surgical complications and preserving the
function of the anal sphincters are increasingly the focus
of treatment of early local rectal cancer at stages T1 and
T2. Local excision of rectal cancers, including TAE,
transanal endoscopic resection and transsacral local





Survival rate (%) Local recurrence (%)
5-year 10-year 5-year 10-year
T1 TAE 16 67 75 38 6.3 6.3
TAE + RT 8 99 63 50 0 0
T2 TAE 40 44 30 10 10.0 15.0
TAE + RT 41 69 61 34 7.3 14.6
RT, radiation therapy; TAE, transanal local excision.
Figure 1 Survival and recurrence rate for patients. (A) Survival curve of patients at T1 stage. (B) Survival curve of patients at T2 stage.
(C) Recurrence curve of patients at T1 stage. (D) Recurrence curve of patients at T2 stage.
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Table 3 Univariate analysis of the prognostic factors
Survival rate (%)
Clinical features Cases (%) 5-year 10-year P
Sex
Male 53 (45.7) 64 58 0.912
Female 63 (54.3) 77 49
Radiotherapy 116 0.623
Yes 52 (44.8) 75 55
No 64 (55.2) 69 51
Recurrence or metastasis 116 <0.01
Yes 32 (27.6) 32 —
No 84 (72.4) 83 72
Tumor diameter, d (cm) 116 0.928
d < 4 cm 109 (94.0) 71 54
d ≥ 4 cm 7 (6.0) 75 —
Distance to anal margin, L (cm) 115 0.128
L < 4 cm 37 (32.2) 87 58
L ≥ 4 cm 78 (67.8) 67 51
Proportion of tumor basal part, C 94 0.269
1/3 < C 69 (73.4) 69 52
1/3 ≤ C < 2/3 24 (25.5) 70 46
C ≥ 2/3 1 (1.1) 100 —
Gross type 101 0.168
Protrusive 72 (71.3) 76 58
Ulcerative 27 (26.7) 42 34
Infiltrative 2 (2.0) 100 —
Pathological type 115 0.025
Well differentiated 80 (69.6) 79 57
Moderately differentiated 19 (16.5) 50 30
Poorly differentiated 16 (13.9) 66 57
Depth of infiltration 116 0.002
Tis 7 (6.0) 100 83
T1 24 (20.7) 93 85
T2 81 (69.8) 60 45
T3 4 (3.4) 50 —
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have constantly shown that for rectal cancer patients with
tumors confined to the rectal wall, the outcomes of local
excision are usually satisfactory [10,11]. Thus, local exci-
sion in the treatment of early rectal cancers is helpful and
should be studied intensively.
Local excision of rectal cancers is an optional therapy
for patients without lymph node metastasis, and its appli-
cation depends on the depth of tumor infiltration, tumor
differentiation and the extent of invasion to lymphatic and
blood vessels [9,12]. According to treatment guidelines
recommended by NCCN together with our clinicalexperience and most researchers’ viewpoints [13,14], we
propose the indications for local excision should in-
clude: (1) a well-differentiated adenocarcinoma; (2) the
depth of tumor invasion is at the Tis to T1 stage; (3) dis-
tal rectal cancer within 8 cm of the anal margin; (4) the
diameter of the tumor is less than 3.0 cm and involves
no more than 1/3 of the rectal perimeter; (5) no vascular
infiltration; (6) no lymph node and distal metastasis;
and (7) patient cannot tolerate major surgery or has de-
veloped severe complications.
Since lymph node dissection is impossible in a local
excision, accurate preoperative staging is especially
Table 4 Multivariate Cox regression analysis of
prognostic factors
Clinical features P Exp (B) 95.0% confidence interval
Sex 0.131 2.076 0.805–5.355
Age 0.186 1.022 0.990–1.056
Tumor diameter 0.434 1.270 0.698–2.312
Distance to anal margin 0.410 0.862 0.607–1.226
Width of tumor basal part 0.216 0.033 0.000–7.369
Gross type 0.610 1.251 0.529–2.956
Pathological type 0.305 1.304 0.785–2.165
T stage 0.042 2.622 1.037–6.625
Adjuvant radiotherapy 0.163 0.480 0.172–1.345
Recurrence or metastasis <0.001 3.025 1.985–4.611
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not. The widely used staging measures include digital rec-
tal examination, enteroscopy, endorectal ultrasonog-
raphy, spiral CT, rectal MRI and positron emission
tomography-CT [15-17]. We adopted CT, MRI and
digital rectal examination.
The 5-year survival rates after a Miles resection, low
anterior resection and ultra-low anterior resection are
70.3%, 72.9% and 73.7%, respectively, and for patients at
stage I, the rate is 90.9% [7,9]. In our study, the overall
5-year survival rate was 72%, while the rates for T1 and
T2 patients were 93% and 63%. This result demonstrates
that for strictly selected cases, local excision is more
suitable for T1 patients. In addition, the recurrence rate
of T2 tumors in this study was far higher than that of
T1 tumors, consistent with previous studies [18,19].
Therefore, we do not recommend the application of
local excision for rectal cancer patients at stage T2.
Most relevant studies have reported that the reason
for the high recurrence after local excision mainly lies in
two aspects. One is the seeding implantation of cancer
cells during the surgery. Though many clinicians recom-
mend a washout during the operation, this does not ne-
cessarily lead to a reduction in the incidence of local
recurrence [10]. In comparison, under the principles of
no contact and whole resection, standard manipulations
and appropriate case selection are more effective in pre-
venting implantation of malignant cells. TAE is difficult
to perform, and the field exposure is also very limited.
The extent of the technical difficulty of a whole tumor
excision is determined by multiple factors, including the
tumor’s gross type, involved perimeter of rectal wall, dis-
tance from the anal margin, and patient’s age and obes-
ity. In the NCCN guideline, one of the standards for
TAE is a tumor diameter less than 3 cm, but there are
also arguments that a standard of 2.5 cm might be more
statistically significant [20]. For rectal cancers with low
hazard factors, if the field is clear and manipulation issimple, then the tumor can be entirely excised while
avoiding implantation of malignant cells.
The other chief factor responsible for the high recur-
rence after local excision is potential lymph node metas-
tasis and insufficient excision of the marginal area. The
probability of lymph node metastasis increases as T stage
advances: at the T1 stage it is 0 to 12%, at the T2 stage it
is 12 to 18%, and at the T3 and T4 stages it is up to 36
to 79% [10]. For rectal cancers involving the mucosa or
submucosa, the probability of lymph node metastasis is
3% to 5%, thus local excision is a theoretically cure treat-
ment. But for those with an infiltrated muscular layer,
because the probability of lymph node metastasis is as
high as 40%, it would be more prudent to consider
adopting TAE to treat T2 rectal cancers. Our statistical
analysis showed that as the T stage increases the incidence
of postoperative recurrence tends to be higher, being 6.3%
for T1 and 14.8% for T2, which is in accordance with
other reports [8,21,22]. Therefore, local excision is only a
palliative therapy.
This study shows that adjuvant radiotherapy can sig-
nificantly decrease the recurrence hazards of T1 and T2
rectal cancer patients, but was not related to their clinical
outcomes (T1: P = 0.184; T2: P = 0.356). The multimodal-
ity treatment schemas combining local excision and radio-
therapy have been reported to be able to improve the local
control rates, as well as better functional outcomes in pa-
tients with higher stage of rectal cancer [23,24]. Though
no conclusion has been reached regarding the standards
of the pre- and postoperative radiotherapy, and related
background factors (such as the doses), most reports have
indicated that compared with sole surgical treatment, sur-
gery combined with preoperative radiotherapy can en-
hance the survival rate and lower the incidence of
recurrence. Also, local excision was considered as an ex-
tended indication for T2-3 rectal cancer patients after
neoadjuvant chemoradiotherapy [25]. Local excision is ef-
ficient in treating T2 patients with distal rectum cancer
who exhibit complete pathologic response to preoperative
chemoradiation [26]. However, in comparison, surgery
with a postoperative radiotherapy will only decrease the
tendency of recurrence while impose on effect on the sur-
vival rate [27,28]. Therefore, preoperative radiotherapy is
strongly recommended for rectal patients.
Conclusion
Our statistical analysis of the 116 TAE-treated rectal can-
cer cases indicates that TAE is an effective therapy for T1
cancers but it is not suitable for patients at the T2 stage.
Tumor pathological type, recurrence or metastasis, and
invasion depth (T staging) are all factors affecting patient
prognosis. Tumors that are poorly differentiated and
deeply infiltrated, and those with recurrence or metastasis,
tend to have poor outcomes. Recurrence or metastasis
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encing survival conditions, and they could increase the
hazard of death. Adjuvant radiotherapy could decrease the
danger of local recurrence after surgery, but may not im-
prove the survival rate. It can be considered a comple-
mentary and auxiliary therapeutic measure.
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